AI MARKET SCANNING

Black Diamond Therapeutics, Inc

🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +0.05%
MAX GAP RECORD +10.86%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $BDTX
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Aug 06, 2026 Earnings Release 2026-08-06 (BEFORE OPEN)
+0.56%
May 07, 2026 Earnings Release 2026-05-07 (BEFORE OPEN)
-1.77%
Mar 16, 2026 Earnings Release 2026-03-16 (AFTER CLOSE)
-3.88%
Nov 06, 2025 Earnings Release 2025-11-06 (BEFORE OPEN)
+0.78%
Aug 07, 2025 Earnings Release 2025-08-07 (BEFORE OPEN)
-4.09%
May 12, 2025 Earnings Release 2025-05-12 (AFTER CLOSE)
+10.86%
Mar 06, 2025 Earnings Release 2025-03-06 (AFTER CLOSE)
-3.16%
Nov 05, 2024 Earnings Release 2024-11-05 (BEFORE OPEN)
+4.68%

VOLATILITY & GAP BIAS

AVG GAP MOVE 2.7%
Bullish Gaps (4)
Bearish Gaps (7)
Neutral / Flat (4)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $BDTX

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗